5. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. 2014; Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 20:398–406. DOI:
10.1111/hae.12344. PMID:
24418368.
Article
7. Berntorp E, Boulyjenkov V, Brettler D, et al. 1995; Modern treatment of haemophilia. Bull World Health Organ. 73:691–701. PMID:
8846496. PMCID:
PMC2486807.
8. Charlebois TS, O'connell BD, Adamson SR, et al. 2001; Viral safety of B-domain deleted recombinant factor VIII. Semin Hematol. 38(2 Suppl 4):32–9. DOI:
10.1053/shem.2001.25891. PMID:
11449333.
Article
9. Roth DA, Kessler CM, Pasi KJ, et al. 2001; Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 98:3600–6. DOI:
10.1182/blood.V98.13.3600. PMID:
11739163.
Article
11. Pierce GF, Haffar A, Ampartzidis G, et al. 2018; First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia. 24:229–35. DOI:
10.1111/hae.13409. PMID:
29537123.
Article
12. Windyga J, Lissitchkov T, Stasyshyn O, et al. 2014; Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia. 20:15–24. DOI:
10.1111/hae.12228. PMID:
23834666.
13. Windyga J, Lin VW, Epstein JD, et al. 2014; Improvement in health- related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study. Haemophilia. 20:362–8. DOI:
10.1111/hae.12315. PMID:
24251442.
14. Windyga J, Lissitchkov T, Stasyshyn O, et al. 2014; Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study. Haemophilia. 20:651–8. DOI:
10.1111/hae.12419. PMID:
24697870.
Article
15. Urasinski T, Stasyshyn O, Andreeva T, et al. 2015; Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial. Haemophilia. 21:196–203. DOI:
10.1111/hae.12548. PMID:
25495591.
16. Yoo KY, Choi YM, Hwang TJ, Choi EJ. 2012; The efficacy of prophylaxis for children with severe hemophilia in Korea - an experience of single institute. Clin Pediatr Hematol Oncol. 19:79–85.
18. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. 2010; Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia. 16:460–8. DOI:
10.1111/j.1365-2516.2009.02162.x. PMCID:
PMC5592798. PMID:
20059559.
19. Shapiro AD, Di Paola J, Cohen A, et al. 2005; The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 105:518–25. DOI:
10.1182/blood-2004-06-2283. PMID:
15383463.
Article
20. Jaffray J, Young G. 2015; Recent trial results in recombinant coagulation factors for the treatment of hemophilia B. Clin Invest (Lond). 5:205–16. DOI:
10.4155/cli.14.118.
Article
22. Puetz J, Soucie JM, Kempton CL, Monahan PE. Hemophilia Treatment Center Network (HTCN). 2014; Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia. 20:25–31. DOI:
10.1111/hae.12229. PMID:
23855900. PMCID:
PMC4520536.
Article
24. Astermark J, Berntorp E, White GC, Kroner BL. MIBS Study Group. 2001; The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 7:267–72. DOI:
10.1046/j.1365-2516.2001.00510.x. PMID:
11380630.
26. Fukutake K, Taki M, Matsushita T, et al. 2019; Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B. Haemophilia. 25:e247–56. DOI:
10.1111/hae.13783. PMCID:
PMC6852692. PMID:
31168882.
Article
27. Valentino LA. 2014; The role of Rixubis
TM in the treatment of hemophilia B. Immunotherapy. 6:381–94. DOI:
10.2217/imt.14.17. PMID:
24815779.